Douglas Robert Andrew's Form 4 filing
Resmed Inc (RMD) · filed Oct 18, 2021
- Accession no.
- 0001127602-21-027245
- Filed
- Oct 18, 2021
- Trade date
- Oct 15, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.05M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Douglas Robert AndrewCIK 0001352232 | Officer (President and COO ResMed Inc.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 15, 2021 | ResMed Common Stock | MOption exerciseAcquired | +8,000 | $58.24 | +$465,920 | 30,149 | Direct | |
| Oct 15, 2021 | ResMed Common Stock | SSaleDisposed | −8,000 | $255.77 | −$2,046,160 | 22,149 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 15, 2021 | ResMed Common Stock | MOption exerciseDisposed | −8,000 | $0.00 | $0 | 102,098 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.